JIA Yingjie's Experience in the Diagnosis and Treatment of Esophageal Cancer
10.16466/j.issn1005-5509.2024.02.006
- VernacularTitle:贾英杰辨治食管癌经验撷菁
- Author:
Dongying LIAO
1
,
2
;
Jiayu LIU
;
Yue LI
Author Information
1. 天津中医药大学第一附属医院 天津 300381
2. 天津中医药大学
- Keywords:
esophageal cancer;
traditional Chinese medicine;
treatment based on pattern differentiation;
regulating Qi;
experience of renowned doctors;
proven cases;
JIA Yingjie
- From:
Journal of Zhejiang Chinese Medical University
2024;48(2):170-173
- CountryChina
- Language:Chinese
-
Abstract:
[Objective]To summarize the clinical experience of Professor JIA Yingjie,a renowned traditional Chinese medicine practitioner in the treatment of esophageal cancer.[Methods]Through clinical following up,collect and analyze Professor JIA's understanding of the etiology and pathogenesis of esophageal cancer and related medication,and a case of was attached as evidence.[Results]Professor JIA believes that the pathogenesis of esophageal cancer can be summarized as"phlegm coagulation and Qi stagnation"in the early stage,"primitive deficiency"in the late stage as a whole,"phlegm and blood stasis intermingle,Qi and blood stasis obstruct the diaphragm"in local areas,phlegm,Qi,and blood stasis solidify and poison transform into cancer turbidity,and block and form tumors.Clinical differentiation and treatment should always focus on"Qi",with a particular emphasis on regulating the"Qi mechanism".The lungs,spleen and liver are in sync,and dynamic differentiation and treatment should be carried out based on the characteristics of the patient's tongue and pulse.Medication should emphasize the use of"strengthening the body resistance righting"and"dispelling pathogenic factors"to achieve the dissipation of blood stasis,the elimination of cancer toxins and the opening of the diaphragm.[Conclusion]Based on the characteristics of esophageal cancer and the patient's physical constitution,Professor JIA combines disease and syndrome differentiation in treating esophageal cancer,providing a certain reference value and new path for clinical medication.
